Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants
“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...
May 5, 2020 | Anti-METH antibody, IXT-m200, Grants
Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Oct 10, 2017 | Anti-METH antibody, IXT-m200, General News, Grants
Little Rock, AR – InterveXion Therapeutics has received a federal grant to fund a second clinical study of IXT-m200, a monoclonal antibody designed to treat methamphetamine abuse. The clinical trial, called STAMPOUT, will be a Phase 2a, parallel-group,...
Jan 29, 2015 | Anti-METH antibody, IXT-m200, Anti-METH Vaccine, General News, Grants, Uncategorized
LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...
Jul 15, 2011 | Anti-METH antibody, IXT-m200, Grants, Uncategorized
A grant to fund the First in Human, Phase 1a clinical study of anti-METH ch-mAb7F9 was awarded to UAMS and InterveXion. This three year, $3 million, award will be used to test the safety of the chimeric antibody in healthy human volunteers.
Oct 1, 2009 | Anti-METH antibody, IXT-m200, Grants, Uncategorized
InterveXion has been awarded a two year $3.9 million grant entitled “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity” by the National Institutes of Health, National Institute on Drug Abuse (NIDA) as part of the American Recovery and...
Recent Comments